Dale MBA - Nutra Pharma Chief Officer
Insider
Dale MBA is Chief Officer of Nutra Pharma Corp
| Age | 64 |
| Phone | 954 509 0911 |
| Web | https://www.nutrapharma.com |
Nutra Pharma Management Efficiency
The company has return on total asset (ROA) of (1.1323) % which means that it has lost $1.1323 on every $100 spent on assets. This is way below average. Nutra Pharma's management efficiency ratios could be used to measure how well Nutra Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Nutra Pharma Corp currently holds 517.18 K in liabilities. Nutra Pharma Corp has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Nutra Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Nutra Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nutra Pharma Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nutra to invest in growth at high rates of return. When we think about Nutra Pharma's use of debt, we should always consider it together with cash and equity.
Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company was incorporated in 2000 and is based in Plantation, Florida. NUTRA PHARMA operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 4 people. Nutra Pharma Corp [NPHC] is a Pink Sheet which is traded between brokers as part of OTC trading. Management Performance
| Return On Asset | -1.13 |
Nutra Pharma Corp Leadership Team
Elected by the shareholders, the Nutra Pharma's board of directors comprises two types of representatives: Nutra Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nutra. The board's role is to monitor Nutra Pharma's management team and ensure that shareholders' interests are well served. Nutra Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nutra Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Neil Roth, Inc Diagnostics | ||
| Dale MBA, Chief Officer | ||
| Erik Deitsch, CEO, Chairman | ||
| Nina Goldstein, Sec |
Nutra Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Nutra Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -1.13 | |||
| Profit Margin | 28.71 % | |||
| Operating Margin | (5.58) % | |||
| Current Valuation | 10.33 M | |||
| Shares Outstanding | 7.6 B | |||
| Shares Owned By Insiders | 1.02 % | |||
| Shares Owned By Institutions | 0.01 % | |||
| Price To Sales | 6.13 X | |||
| Revenue | 51.9 K | |||
| Gross Profit | 8.47 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Nutra Pink Sheet
Nutra Pharma financial ratios help investors to determine whether Nutra Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nutra with respect to the benefits of owning Nutra Pharma security.